121 related articles for article (PubMed ID: 9447279)
1. Clinical usefulness of urinary CrossLaps as a sensitive marker of bone metabolism.
Nakayama H; Yano T; Sagara Y; Ando K; Kasai Y; Taketani Y
Endocr J; 1997 Aug; 44(4):479-84. PubMed ID: 9447279
[TBL] [Abstract][Full Text] [Related]
2. Serum osteocalcin and urinary crosslaps are suitable markers of bone turnover in response to short-term hormone replacement therapy.
Peichl P; Griesmacher A; Müller MM; Marteau R; Kumpan W; Bröll H
Gynecol Endocrinol; 2000 Oct; 14(5):374-81. PubMed ID: 11109977
[TBL] [Abstract][Full Text] [Related]
3. Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy.
Marshall LA; Cain DF; Dmowski WP; Chesnut CH
Obstet Gynecol; 1996 Mar; 87(3):350-4. PubMed ID: 8598953
[TBL] [Abstract][Full Text] [Related]
4. Biochemical markers as predictors of bone mineral density changes after GnRH agonist treatment.
Borderie D; Cherruau B; Dougados M; Ekindjian OG; Roux C
Calcif Tissue Int; 1998 Jan; 62(1):21-5. PubMed ID: 9405728
[TBL] [Abstract][Full Text] [Related]
5. Change in C-terminal cross-linking domain of type I collagen in urine, a new marker of bone resorption, during and after gonadotropin-releasing hormone agonist administration.
Taga M; Minaguchi H
Eur J Endocrinol; 1997 Aug; 137(2):167-71. PubMed ID: 9272105
[TBL] [Abstract][Full Text] [Related]
6. Specific changes of urinary excretion of cross-linked N-telopeptides of type I collagen in pre- and postmenopausal women: correlation with other markers of bone turnover.
Gorai I; Taguchi Y; Chaki O; Nakayama M; Minaguchi H
Calcif Tissue Int; 1997 Apr; 60(4):317-22. PubMed ID: 9075625
[TBL] [Abstract][Full Text] [Related]
7. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.
Garnero P; Gineyts E; Riou JP; Delmas PD
J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361
[TBL] [Abstract][Full Text] [Related]
8. Serum crosslaps in comparison to serum osteocalcin and urinary bone resorption markers.
Peichl P; Griesmacherb A; Marteau R; Hejc S; Kumpan W; Müller MM; Bröll H
Clin Biochem; 2001 Mar; 34(2):131-9. PubMed ID: 11311223
[TBL] [Abstract][Full Text] [Related]
9. Association between female sex hormones and biochemical markers of bone turnover in peri- and postmenopausal women.
Peichl P; Griesmacher A; Pointinger P; Marteau R; Hartl W; Gruber W; Bröll H
Calcif Tissue Int; 1998 May; 62(5):388-94. PubMed ID: 9541515
[TBL] [Abstract][Full Text] [Related]
10. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline.
Okabe R; Inaba M; Nakatsuka K; Miki T; Naka H; Moriguchi A; Nishizawa Y
J Bone Miner Metab; 2004; 22(2):127-31. PubMed ID: 14999523
[TBL] [Abstract][Full Text] [Related]
11. Effect of treatment with GnRH agonists on new markers of bone metabolism.
Kukuvitis A; Bildiris J; Prapas Y; Tsamis D; Papadimas J; Dimitriadou A; Vlassis G
Gynecol Obstet Invest; 1999; 47(3):194-6. PubMed ID: 10087416
[TBL] [Abstract][Full Text] [Related]
12. The effect of gonadotropin-releasing hormone agonist on type I collagen C-telopeptide and N-telopeptide: the predictive value of biochemical markers of bone turnover.
Amama EA; Taga M; Minaguchi H
J Clin Endocrinol Metab; 1998 Feb; 83(2):333-8. PubMed ID: 9467536
[TBL] [Abstract][Full Text] [Related]
13. Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH.
Ueda M; Inaba M; Okuno S; Maeno Y; Ishimura E; Yamakawa T; Nishizawa Y
Life Sci; 2005 Jul; 77(10):1130-9. PubMed ID: 15978265
[TBL] [Abstract][Full Text] [Related]
14. High bone density in hyperandrogenic women: effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen-progestin replacement.
Simberg N; Tiitinen A; Silfvast A; Viinikka L; Ylikorkala O
J Clin Endocrinol Metab; 1996 Feb; 81(2):646-51. PubMed ID: 8636283
[TBL] [Abstract][Full Text] [Related]
15. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
[TBL] [Abstract][Full Text] [Related]
16. Changes in bone turnover during the menstrual cycle in cynomolgus monkeys.
Hotchkiss CE; Brommage R
Calcif Tissue Int; 2000 Mar; 66(3):224-8. PubMed ID: 10666499
[TBL] [Abstract][Full Text] [Related]
17. [Usefulness of osteocalcin and CrossLaps as markers of bone turnover in children with chronic renal failure].
Polak-Jonkisz D; Zwolińska D; Bednorz R; Owczarek H; Nahaczewska W
Pol Merkur Lekarski; 2002 Apr; 12(70):257-60. PubMed ID: 12089882
[TBL] [Abstract][Full Text] [Related]
18. Serum soluble interleukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle.
Gorai I; Taguchi Y; Chaki O; Kikuchi R; Nakayama M; Yang BC; Yokota S; Minaguchi H
J Clin Endocrinol Metab; 1998 Feb; 83(2):326-32. PubMed ID: 9467535
[TBL] [Abstract][Full Text] [Related]
19. Parathyroidectomy for primary hyperparathyroidism induces positive uncoupling and increases bone mineral density in cancellous bones.
Abe Y; Ejima E; Fujiyama K; Kiriyama T; Ide A; Sera N; Tominaga T; Ashizawa K; Yokoyama N; Eguchi K
Clin Endocrinol (Oxf); 2000 Feb; 52(2):203-9. PubMed ID: 10671948
[TBL] [Abstract][Full Text] [Related]
20. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
